Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Business & Industry
- Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab)
- The Pfizer Foundation invests in 20 organizations tackling infectious diseases and antimicrobial resistance
- Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
- Roche's first FDA-approved tumour-agnostic medicine
- Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
Research & Development
- Preventing tumor metastasis
- Study finds lack of racial diversity in cancer drug clinical trials
- Drug accelerates blood system's recovery after chemotherapy, radiation
- New drug shows encouraging survival in pancreatic cancer
- Ancient natural history of antibiotic production and resistance revealed
- Eating more plant-based foods may be linked to better heart health
- Rye is healthy, thanks to an interplay of microbes
Conferences & Events
- Respiratory Drug Delivery 2019
- Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference
- eyeforpharma The Marketing Disruption Summit
- Optima to host post-conference workshop at Lyophilization USA
- The need for a blueprint emergency plan to avoid a HPAPI crisis
- Ophthalmic Drugs Conference 2019
- Lyophilization USA Conference 2019
Regulatory Affairs
- FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
- FDA approves first therapy for rare joint tumor
- FDA approves first treatment for severe hypoglycemia that can be administered without an injection
- FDA approves first generics of Lyrica
- FDA approves new treatment for refractory multiple myeloma